Age had no effect on empagliflozin’s ability to reduce the risk of cardiovascular death and heart failure hospitalization in those with heart failure with preserved ejection fraction (HFpEF), and the drug was well-tolerated in older patients, according to a new analysis of the EMPEROR-Preserved trial.